Published in Lipids Health Dis on September 18, 2003
Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk (1996) 6.18
Homocysteine and vascular disease. Lancet (1999) 5.24
Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA (1997) 3.87
The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta (1984) 3.58
Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation (1998) 3.42
Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol (1992) 2.57
Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem (1998) 1.55
Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol (1996) 1.34
Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int (2002) 1.27
Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation (1996) 1.19
Dietary fats and coronary heart disease. Lancet (1980) 1.12
Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant (2000) 1.09
Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol (1997) 0.99
High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int (1996) 0.98
Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr (2001) 0.98
Abnormal fatty acid composition and human atherosclerosis. Postgrad Med J (1974) 0.96
The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol (1993) 0.96
Altered fatty acid metabolism in patients with angiographically documented coronary artery disease. Metabolism (1994) 0.89
Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. Am J Clin Nutr (1996) 0.88
Abnormal fatty acid profile in chronic hemodialysis patients: possible deficiency of essential fatty acids. Clin Physiol Biochem (1990) 0.87
Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl (1996) 0.86
A new relationship between total/high density lipoprotein cholesterol and polyunsaturated fatty acids. Lipids (1996) 0.84
Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int (2000) 0.83
Red blood cell fatty acid profile of chronic renal failure patients receiving maintenance haemodialysis treatment. Prostaglandins Leukot Essent Fatty Acids (2002) 0.82
Evidence of altered homocysteine metabolism in chronic renal failure. Nephron (1999) 0.81
Lipid abnormalities in chronic renal failure patients undergoing hemodialysis. Medicina (B Aires) (2001) 0.80
Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis (1995) 0.80
Hyperlipidemia of chronic renal failure. Blood Purif (1994) 0.79
Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int (1999) 0.79
Putative atherogenic factors in patients with chronic renal failure. Prog Cardiovasc Dis (1983) 0.79
Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab (1996) 0.78
Variations in the lipid profile of patients with chronic renal failure, treated with folic acid. Int J Vitam Nutr Res (2003) 0.77
Short-chain aliphatic alcohols increase rat-liver microsomal membrane fluidity and affect the activities of some microsomal membrane-bound enzymes. Biochim Biophys Acta (1984) 0.77
Dietary fat and hormonal effects on erythrocyte membrane fluidity and lipid composition in adult women. Metabolism (1989) 0.77
Polyunsaturated fatty acids and myocardial infarction. Lancet (1970) 0.77
Variations in the lipid profile of patients with chronic renal failure, treated with folic acid. Int J Vitam Nutr Res (2003) 0.77